With many new agents under development, including targeted therapies for gastric cancer, there is a need for predictive research models such as Patient Derived Xenografts (PDX) for preclinical evaluation. PDX models are proven to be highly predictive models for preclinical drug assessment. The CrownBio collection contains over 100 well characterized gastric cancer PDX models, including EGFR amplified models and cachexic models. Learn more about these models in the following publications: More
-A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.pdf
-Stromal-Based Signatures for the Classification of Gastric Cancer.pdf
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.